Nuvectis Pharma (NVCT) CEO awarded 150,000 restricted shares as equity pay

Rhea-AI Filing Summary

Nuvectis Pharma, Inc. reported an equity award to its Chairman and CEO, Ron Bentsur. On 01/06/2026, he was granted 150,000 shares of restricted common stock at a price of $0 per share. These restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues to serve with the company on each vesting date.

After this grant, Mr. Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, held directly, which includes previously granted restricted shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENTSUR RON

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		150,000(1)	A	$0	3,675,924(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Bentsur's continued service on such dates.

2. Includes shares of restricted common stock.

	/s/ Ron Bentsur	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvectis Pharma (NVCT) report in this Form 4?

The filing reports that Chairman and CEO Ron Bentsur received an award of 150,000 shares of restricted common stock of Nuvectis Pharma, Inc. on 01/06/2026.

How many Nuvectis Pharma (NVCT) shares were granted to Ron Bentsur and at what price?

Ron Bentsur was granted 150,000 shares of Nuvectis Pharma common stock at a price of $0 per share, reflecting a restricted stock award rather than an open-market purchase.

What is the vesting schedule for Ron Bentsur’s 150,000 restricted Nuvectis Pharma shares?

The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, subject to Mr. Bentsur’s continued service on each vesting date.

How many Nuvectis Pharma (NVCT) shares does Ron Bentsur own after this transaction?

Following the reported grant, Ron Bentsur beneficially owns 3,675,924 shares of Nuvectis Pharma common stock, including restricted shares, held directly.

What roles does Ron Bentsur hold at Nuvectis Pharma (NVCT)?

Ron Bentsur is a Director, a 10% owner, and serves as Chairman & CEO of Nuvectis Pharma, Inc.

Was this Nuvectis Pharma Form 4 filed for a direct or indirect ownership change?

The filing shows the 150,000 restricted shares as being held under direct ownership by Ron Bentsur.